Cargando…

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting

BACKGROUND: Since oral direct-acting antiviral agents (DAAs) became available, the global hepatitis C treatment situation has undergone tremendous changes. However there are still many issues worthy of attention in treatment. METHODS: We selected 53 HCV-infected patients who were treated and followe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hongyu, Liu, Jianxiang, Kang, Qian, Luo, Hao, Tan, Ning, Pan, Jiali, Yang, Yuqing, Yu, Min, Liu, Dan, Xi, Hongli, Han, Yifan, Cheng, Ran, Yu, Yanyan, Xu, Xiaoyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250317/ https://www.ncbi.nlm.nih.gov/pubmed/35789797 http://dx.doi.org/10.2147/IDR.S352873

Ejemplares similares

The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)

An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA
por: Hansoongnern, Payuda, et al.
Publicado: (2023)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014)

Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
por: Long, Lu, et al.
Publicado: (2014)

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection
por: Wang, Yuhan, et al.
Publicado: (2021)

Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay
por: Hadziyannis, Emilia, et al.
Publicado: (2013)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
por: Rinaldi, Luca, et al.
Publicado: (2020)

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals
por: Akuta, Norio, et al.
Publicado: (2023)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure
por: Rodrigues, João Paulo Vilela, et al.
Publicado: (2022)

Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2016)

356. HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment
por: Michienzi, Sarah M, et al.
Publicado: (2019)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Basso, Monica, et al.
Publicado: (2021)

A Higher Correlation of HCV Core Antigen with CD4+ T Cell Counts Compared with HCV RNA in HCV/HIV-1 Coinfected Patients
por: Shen, Tao, et al.
Publicado: (2011)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy
por: Ghiglione, Yanina, et al.
Publicado: (2020)

Identification of the transcripts associated with spontaneous HCV clearance in individuals co-infected with HIV and HCV
por: Chen, Yue, et al.
Publicado: (2016)

Expression of core antigen of HCV genotype 3a and its evaluation as screening agent for HCV infection in Pakistan
por: Yousaf, Muhammad Z, et al.
Publicado: (2011)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
por: Poizot-Martin, Isabelle, et al.
Publicado: (2015)

Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral Therapy
por: Lapa, Daniele, et al.
Publicado: (2021)

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies
por: Grebely, Jason, et al.
Publicado: (2018)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_41v4d2jovs1jdfs11i9paa5hk0